Resolving the immune response across clonal cancer evolution in situ with Atera whole transcriptome profiling

Cancer is not a single, uniform mass of cells. It is a living, shifting landscape where different groups of cells, each with their own unique genetic history, grow side by side. These groups, called clones, evolve over time, competing for space and resources within the tumor. To understand how a tumor grows and how the body's immune system tries to fight it, scientists need to see this landscape in high definition. For years, researchers could look at the genes inside individual cells, but they lost the map of where those cells were located in the tissue. Alternatively, they could see the tissue structure, but they had to guess the genetic details of the cells inside. The goal has long been to combine these two views: to see exactly which cells are neighbors, what their genetic makeup is, and how they interact, all within the same piece of tissue.

A new study from Stanford University offers a powerful step toward this goal by testing a cutting-edge technology called Atera. This tool allows scientists to read the entire genetic instruction manual of thousands of individual cells while keeping them in their original positions within a tissue sample. The researchers applied this technology to human breast tissue affected by ductal carcinoma in situ, an early form of breast cancer where abnormal cells are contained within milk ducts. They compared Atera against two existing technologies that look at only a small, pre-selected list of genes. The results showed that Atera could see far more detail, revealing rare cell types and subtle genetic changes that the other tools missed. Most importantly, the team used this high-resolution view to map out the family tree of the cancer cells and track how the immune system's response changed as the cancer evolved.

The researchers began by analyzing tissue samples from patients with ductal carcinoma in situ. They used three different methods to scan the tissue: two established tools that focus on a limited set of genes, and the new Atera system, which reads nearly every gene in the cell. The difference in what they could see was stark. While the older tools detected a few thousand genetic messages per cell, Atera found nearly twenty-eight times more. This massive increase in detail meant that Atera could identify specific types of cells that the other methods simply could not distinguish. For example, it found rare immune cells known as dendritic cells, which act as sentinels for the body's defense system. In the data from the older tools, these rare cells were invisible, and many immune cells could not be classified beyond a general category. Atera, however, could sort them into precise groups, revealing a much richer and more complex immune environment than previously understood.

With this detailed map of cell types, the team turned their attention to the cancer cells themselves. They wanted to know if the different groups of cancer cells were genetically distinct and how they were related. Because the Atera system reads so many genes, it could detect tiny changes in the number of copies of specific chromosomes, known as copy number variations. These changes act like genetic fingerprints. By looking at these fingerprints, the researchers could separate the cancer cells into four distinct clones, each with its own unique genetic signature. They then reconstructed the evolutionary history of the tumor, showing how a single original cancer cell gave rise to these different branches. One branch, which appeared early, had a specific set of genetic changes, while later branches acquired additional changes, such as a large gain of genetic material on chromosome 11. This allowed the scientists to draw a family tree of the cancer, showing exactly how the tumor grew and diversified within a single tissue sample.

To ensure these findings were real and not just an artifact of the technology, the researchers performed a rigorous check. They took physical sections of the same tissue block used for the Atera scan and carefully cut out sixteen small regions of the tumor ducts. They then sequenced the DNA from these regions directly, a method that provides a definitive ground truth. The genetic changes they found in the DNA were highly concordant with the patterns predicted by the Atera system, containing the same set of alterations inferred from the transcriptome. This confirmed that the new technology could accurately reconstruct the tumor's evolutionary history without needing to destroy the tissue or lose its spatial context. It was the first time such a detailed copy-number map from a single-cell spatial tool had been validated against direct DNA sequencing.

The final piece of the puzzle was to see how the immune system interacted with these evolving cancer clones. The researchers mapped the location of the immune cells relative to the different cancer clones. They discovered that the immune response was not uniform across the tumor. As the cancer clones evolved and became more advanced, the surrounding immune environment changed. Specifically, the fraction of the immune niche surrounding the ducts of later, more evolved clones increased compared to earlier clones. This suggests that as the tumor grows and changes, it actively reshapes its local environment, potentially recruiting or altering the immune cells around it. The study showed that these interactions could be tracked in real space, revealing that the immune response is dynamic and closely tied to the specific genetic stage of the cancer cells.

This work establishes a new standard for studying cancer in its native environment. By combining the ability to read the full genetic code of individual cells with the power to see where they are located, scientists can now watch the drama of cancer evolution unfold in high definition. The study proves that it is possible to reconstruct the family tree of a tumor and simultaneously observe how the body's defenses react to each branch of that tree. While the findings come from a single type of early breast cancer, the approach provides a validated framework for understanding the complex interplay between tumor genetics and the immune system. This level of detail could eventually help researchers understand why some tumors respond to treatment while others do not, by revealing the specific genetic and immune landscapes that define them.